TSHA

Taysha Gene Therapies Inc

TSHA.US tayshagtx.com + Research + Basket
CIK 0001806310
Employees 99
Phone 214 612 0000
Fiscal year end December
IPO Sep 24, 2020
Address 3000 Pegasus Park Drive, Dallas, TX, United States, 75247
4.09
-0.27 (-6.19%)
USD · NASDAQ
52-week range
3.46
7.30
Trading at 17% of the 52-week range
Market Cap
1.42B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.19
Div. Yield
N/A
% Institutions
94.56%
% Insiders
9.45%

1 Year

+1.5%

3 Year

+68.3%

10 Year

-83.0%
Description

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Actions

Add an action for TSHA.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Sean P. Nolan CEO & Chairman 1968
Dr. Sukumar Nagendran M.D. President, Head of Research & Development and Director 1967
Mr. Kamran Alam CPA, M.B.A. CFO & Corporate Secretary 1978
Hayleigh Collins Director of Corporate Communications & Investor Relations NA
Mr. Michael B. Johannesen Chief Legal Officer & Corporate Secretary 1966
Mr. Frederick Porter Ph.D. Chief of Staff & Technical Operations Officer NA
Ms. Emily McGinnis M.P.H. Chief Patient & External Affairs Officer NA
Mr. Sean McAuliffe Chief Business Officer NA
Dr. Steven Gray Ph.D. Chief Scientific Advisor of UT Southwestern Gene Therapy Program NA
Berge Minassian M.D. Chief Medical Advisor of UT Southwestern Gene Therapy Program NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Apr 10, 2026 Sukumar Nagendran N/A Sale 200.00K $4.46 $892.00K SEC
Feb 04, 2026 Kamran Alam N/A Sale 1.66K $4.52 $7.48K SEC
Jan 26, 2026 Kamran Alam N/A Sale 23.85K $4.61 $109.94K SEC
Jan 26, 2026 Sean P Nolan N/A Sale 41.31K $4.61 $190.45K SEC
Jan 26, 2026 Sukumar Nagendran N/A Sale 26.92K $4.61 $124.09K SEC
Jan 23, 2026 Kamran Alam N/A Sale 78.97K $4.75 $375.10K SEC
Jan 23, 2026 Sean P Nolan N/A Sale 136.79K $4.75 $649.75K SEC
Jan 23, 2026 Sukumar Nagendran N/A Sale 89.13K $4.75 $423.38K SEC
Jan 12, 2026 Sukumar Nagendran N/A Sale 200.00K $4.71 $942.00K SEC
Dec 01, 2025 Sukumar Nagendran N/A Sale 260.05K $4.51 $1.17M SEC
Nov 28, 2025 Sukumar Nagendran N/A Sale 110.13K $4.75 $523.09K SEC
Sep 10, 2025 Sukumar Nagendran N/A Sale 200.00K $3.23 $646.00K SEC
May 30, 2025 Paul B Manning N/A Purchase 750.00K $2.75 $2.06M SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
venBio Select Advisor LLC 23.89M Jun 30, 2026 7.35% $1.46 10.09%
RA Capital Management, LLC 23.56M Jun 30, 2026 7.25% $1.39 0.00%
The Goldman Sachs Group Inc 22.71M Jun 30, 2026 6.99% $0.01 1.54%
BlackRock Inc 20.69M Jun 30, 2026 6.37% $0.00 12.67%
Vestal Point Capital LP 19.42M Jun 30, 2026 5.98% $3.09 7.86%
Morgan Stanley - Brokerage Accounts 16.49M Jun 30, 2026 5.08% $0.01 -8.23%
RTW INVESTMENTS, LLC 13.56M Jun 30, 2026 4.17% $0.79 -0.88%
FMR Inc 13.34M Jun 30, 2026 4.11% $0.00 -6.88%
Vanguard Capital Management, LLC 12.48M Jun 30, 2026 3.84% $0.00 21.96%
State Street Corp 11.42M Jun 30, 2026 3.52% $0.00 1.90%
Siren, L.L.C. 9.85M Jun 30, 2026 3.03% $1.36 11.51%
Octagon Capital Advisors LP 9.69M Jun 30, 2026 2.98% $5.93 9.41%
Geode Capital Management, LLC 6.56M Jun 30, 2026 2.02% $0.00 18.59%
Polar Capital Holdings PLC 5.12M Jun 30, 2026 1.58% $0.08 -9.50%
MPM Oncology Impact Management LP 4.50M Jun 30, 2026 1.39% $1.87 0.00%
D. E. Shaw & Co LP 4.40M Jun 30, 2026 1.35% $0.01 -0.65%
Baker Bros Advisors LP 4.00M Jun 30, 2026 1.23% $0.14 0.00%
Wellington Management Company LLP 3.98M Jun 30, 2026 1.22% $0.00 534.71%
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND 3.89M Jun 30, 2026 1.20% $0.04 34.76%
Casdin Capital, LLC 3.25M Jun 30, 2026 1.00% $1.11 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 9.19M 2.83% ▲ 0.21% Sep 30, 2026
2 iShares Russell 2000 ETF 6.71M 2.07% ▼ 0.41% Oct 29, 2026
3 State Street® SPDR® S&P® Biotech ETF 5.37M 1.65% ▼ 0.80% Oct 29, 2026
4 Polar Capital Biotech S Inc 4.85M 1.49% ▲ 0.00% Sep 30, 2026
5 Fidelity Growth Company Fund 4.17M 1.28% ▲ 0.00% Aug 31, 2026
6 Fidelity Small Cap Index 2.62M 0.81% ▲ 0.86% Jul 31, 2026
7 iShares Russell 2000 Growth ETF 2.51M 0.77% ▲ 0.25% Oct 29, 2026
8 Pictet-Biotech P USD 2.25M 0.69% ▲ 43.24% Jul 31, 2026
9 abrdn Life Sciences Investors 2.15M 0.66% ▲ 14.44% Sep 30, 2026
10 iShares Biotechnology ETF 2.06M 0.64% ▼ 0.19% Oct 29, 2026

Financial Highlights

▼
Market Cap: $1.42B
EBITDA: $-151.99M
Book Value: $1.19
Earnings/Share: $-0.41
Profit Margin: 0.00%
Operating Margin: -2,792.33%
ROA (TTM): -23.82%
ROE (TTM): -47.06%
Revenue (TTM): $5.49M
Revenue/Share (TTM): $0.02
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 171.30%

Valuation Metrics

Enterprise Value: $935.60M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 325.83M
Shares Float: 232.62M
% Insiders: 9.45%
% Institutions: 94.56%
Shares Short: 51.25M
Shares Short (Prior Month): 55.02M
Short Ratio: 10.79
Short % Float: 15.98%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$9.77M
Cost of Goods Sold
adjust
$-1.15M
Gross Profit
subtotal
$9.77M
SG&A
adjust
$-33.87M
R&D
adjust
$-86.40M
Operating Income
subtotal
$-110.50M
Other / Non-Operating Items
adjust
$1.50M
Net Income
subtotal
$-109.00M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TSHA.US!